MET Amplification
7
4
4
1
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
0.0%
0 terminated out of 7 trials
100.0%
+13.5% vs benchmark
0%
0 trials in Phase 3/4
0%
0 of 1 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 1 completed trials
Clinical Trials (7)
Study of Crizotinib for ROS1 and MET Activated Lung Cancer
Osimertinib Combined With Savolitinib in the Treatment of NSCLC With Low Copy Number MET Amplification
APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors
The Efficacy and Safety of LMV-12 Combined With Osimertinib in NSCLC
Neoadjuvant Immunotherapy in Rare Mutations Localized NSCLC
Lorlatinib Combinations in Lung Cancer
Tepotinib in Solid Tumors Harboring MET Alterations